DiagnoCure’s PCA3 gets boost from GSK study

Two major studies presented last week at the Genitourinary symposium of the American Society of Clinical Oncology in San Francisco featured DiagnoCure’s PCA3 molecular test on subsets of patients in GlaxoSmithKline’s REDUCE trial of its prostate cancer drug dutasteride.

“This four-year, multicentre, worldwide study is the largest to date performed on DiagnoCure’s PCA3 marker,” DiagnoCure (TSX:CUR) president Dr. Yves Fradet said in a statement.

“These results indicate that the PCA3 test can help reduce unnecessary prostate biopsies and help identify patients that have a more aggressive cancer, representing a step forward in personalized patient care,” he added.

The two abstracts are available at:

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID=30817

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID=30866